This report provides exclusive insights into the COVID-19 impact on the Chronic Idiopathic Constipation Therapeutic Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Chronic Idiopathic Constipation Therapeutic Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Chronic Idiopathic Constipation Therapeutic Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.
A recent report published by Infinium Global Research on
chronic idiopathic constipation therapeutic market provides an in-depth analysis
of segments and sub-segments in the global as well as regional chronic
idiopathic constipation therapeutic market. The study also highlights the
impact of drivers, restraints, and macro indicators on the global and regional
chronic idiopathic constipation therapeutic market over the short term as well
as long term. The report is a comprehensive presentation of trends, forecast
and dollar values of global chronic idiopathic constipation therapeutic market.
According to the report, the global chronic idiopathic constipation therapeutic
market is projected to grow at a healthy CAGR over the forecast period of
Constipation can be defined as a state of unsatisfactory
bowel movement, with characteristics of unusual stools and difficulty in
passing stools, or both. Chronic idiopathic constipation (CIC) is an advancing
condition without any known cause or identified underlying illness. Chronic
idiopathic constipation is one of the most frequent gastrointestinal
disorders globally with an evaluation of 35 million population living with
chronic idiopathic constipation, affecting approximately 14% of the adults. CIC
can be classified into three subtypes: dyssynergic defecation (DD), a problem
with rectal evacuation; slow transit constipation; and normal transit
constipation, which is the most common subtype. Patients with CIC usually have
symptoms such as reduced frequency of defecation, hard or lumpy stools,
straining at stool, a sensation of incomplete evacuation or blockage, and some
may also complain about abdominal pain and bloating. In general, symptoms are
chronic if they have been present for at least 3 months.
Changing lifestyle as well as modern food habits causing a decrease in fluid and fiber intake in the diet, changes in water balance and
changes in contractility of the colon are the risk factors leading to chronic
idiopathic constipation, thereby driving the chronic idiopathic constipation
therapeutic market. Additionally, raising awareness about the treatment,
increasing geriatric population and easy accessibility of over-the-counter
drugs may also fuel the chronic idiopathic constipation therapeutic market.
However, less diagnosis due to lack of symptoms for the disease, alternative
treatments and insufficient approved treatment for CIC may hinder the growth of
the chronic idiopathic constipation therapeutic market. Increase in healthcare
expenditure and extensive research in effective drugs manufacturing for
treatment will increase the opportunity for chronic idiopathic constipation therapeutic market in the future.
Geographically the chronic idiopathic constipation
therapeutic market is segmented in regions like North America, Europe, Asia
Pacific, Middle East, and Africa. Due to the high prevalence of chronic
idiopathic constipation, North-America will dominate the market during the
forecast period. The Asia-pacific market is estimated to grow due to the rise
in the acceptability of CIC treatments in countries like India and China.
Whereas, the Europe market will develop in the future due to key players focus
on new treatment and product launch for chronic idiopathic constipation.
The report on global chronic idiopathic constipation
therapeutic market covers segments such as drug class, route of administration,
and distribution channel. On the basis of drug class, the sub-markets include
emollients, laxatives, bulk-forming agents, osmotic agents, and other drug
class. On the basis of route of administration, the sub-markets include oral,
and parental. On the basis of distribution channel, the sub-markets include
hospital pharmacies, retail pharmacies, and online pharmacies.
The report provides profiles of the companies in the market
such as GlaxoSmithKline Plc., Bayer AG, Astellas Pharma, Inc., Sanofi S.A.,
Pfizer, Inc., Ironwood Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, and Other
The report provides deep insights into the demand forecasts,
market trends, and micro and macro indicators. In addition, this report
provides insights into the factors that are driving and restraining the growth
in this market. Moreover, The IGR-Growth Matrix analysis given in the report
brings an insight into the investment areas that existing or new market players
can consider. The report provides insights into the market using analytical
tools such as Porter's five forces analysis and DRO analysis of chronic
idiopathic constipation therapeutic market. Moreover, the study highlights
current market trends and provides forecast from 2019-2025. We also have
highlighted future trends in the market that will affect the demand during the
forecast period. Moreover, the competitive analysis given in each regional
market brings an insight into the market share of the leading players.